News

Here’s what to expect from Blue Shield of California’s four-day closure over Obamacare losses.

CMS expands bundle payment programs by adding cardiac care. Here’s how you can contribute to providers’ success.

PCSK9 inhibitors such as alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) are priced too high to benefit the US healthcare system, according to a new study.

As Aetna bows out of health insurance exchanges, more questions about viability are cropping up. Find out which other plans are exiting the health insurance exchanges.

FDA recently approved granisetron (Sustol, Heron Therapeutics) extended-release injection to prevent nausea and vomiting associated with repeat courses of chemotherapy.

Here is a list of critical concepts physician leaders must master-and instill in others-in order to thrive.

Outsourcing means giving up a vital part of what you do as a business, so it’s a strategy that should be approached carefully. On the other hand, not outsourcing could also threaten the success of your organization.

The presidential hopefuls have very different views about the ACA. Expect three healthcare things that will stay the same even after Obama leaves office.

In an era when legislators, pharmacy benefit managers and others continue to protest the high cost of hepatitis C drugs, new drugs to treat the disease are welcomed. FDA recently approved ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets (Viekira XR, AbbVie) to treat patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection, including those with cirrhosis. AbbVie already markets Viekira Pak, which competes with Harvoni and Sovaldi (Gilead Sciences).

A survey from Vizient of CMS previews reports from member hospitals. Here are the findings.

To generate leads, convert prospects and keep members engaged, health plans must employ a high-touch, multi-channel healthcare marketing strategy which will be much more effective and enroll members who may have not otherwise done so.

Merck’s Wall Street value is climbing after its cancer drug pembrolizumab (Keytruda) received yet another approval from FDA.

New NCCN guidelines include new technology as an option for patients’ annual screening.

Many healthcare organizations lack the necessary governance principles, guidelines, and processes necessary for success in today’s technology-dependent environment.

For healthcare organizations, now is the time to help address Zika fears by utilizing digital tools.

What has you counting sheep at night? Answers from your peers may surprise you.

When Express Scripts and CVS Health announced their 2017 formularies on August 1, a common theme emerged among the healthcare giants: several blockbuster drugs will be removed from both companies’ formularies and lower-cost options such as biosimilars are being embraced.

Systematic review provides comprehensive first look at TNF-alpha biosimilar treatments.

Doctors in these states are now eligible for CPC+. Experts share how to prepare.

Below are some perspectives on what these complaints mean for the parties’ chances and for consolidation in healthcare more generally.

Now a little more than halfway through 2016, it’s time to look at trends in the industry and how they will shape the relationships among stakeholders for the years to come.

As ACOs continue to grow in the healthcare sector, it is imperative that a liaison is in place to act as an intermediary between ACO members and patients to help achieve desired outcomes.

This May, CMS published a final rule addressing Medicaid managed care, through which the regulatory requirements for both the Medicaid MCOs and for states managing the plans has become even more complex.

Risk adjustment has great potential if you follow these three simple rules.

As hospitals begin to search for key post-acute providers and implement new care pathways, providers should be aware of program waivers that afford greater flexibility in determining the most cost-effective care possible to ensure good outcomes for patients within the CJR model.

How one health system and one health plan are fighting the obesity epidemic

AHIP’s president and CEO Marilyn Tavenner discusses the association’s top priorities, challenges, and opportunities.

A senator is investigating whether Medicare's prescription drug benefit is vulnerable to manipulation by pharmaceutical companies after an exclusive Associated Press report showed that Medicare’s spending on certain drugs soared by 85 percent.